Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.

Conference Call and Webcast Information

Event:

Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call

Date:

Thursday, November 14, 2024

Time:

10:00am ET

Conference Call:

1-877-877-1275 (U.S.)

1-412-858-5202 (international)

Webcast:

Webcast | Third Quarter 2024 Financial Results and Business Update Conference Call

About Biofrontera Inc.

Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.

1 – https://www.skincancer.org/skin-cancer-information/actinic-keratosis/

Contacts:

Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com

SOURCE: Biofrontera Inc.

View the original press release on accesswire.com

Staff

Recent Posts

Interim Report January – September 2024: Strong Sales Growth Driven by Accelerated Sensor Sales

UPPSALA, SE / ACCESSWIRE / November 06, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) Press release: Uppsala, November…

35 mins ago

Spago Nanomedical Interim Report January-September 2024

LUND, SWEDEN / ACCESSWIRE / November 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Progress for the…

35 mins ago

Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite…

35 mins ago

“The Senior Care Influencer” Lance A. Slatton becomes Official Brand Ambassador for Echobox Memory Vault

LIVONIA, MI / ACCESSWIRE / November 6, 2024 / Lance A. Slatton, known throughout the…

35 mins ago

Duoning Biotech announced strategic partnership with Branca Bunús to promote the next generation of transfection reagents

SHANGHAI, Nov. 5, 2024 /PRNewswire/ -- Duoning Biotechnology Group ("Duoning") announced a strategic partnership agreement…

4 hours ago

Research Grid raises $6.5 million to make clinical trials admin-free

NEW YORK, Nov. 5, 2024 /PRNewswire/ -- Research Grid, the AI startup that helps medical research…

4 hours ago